Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Actinium Pharmaceuticals Stock Down 4.9 % Shares of ATNM opened at $1.17 on Friday. The stock has a market capitalization of $36.50 million, a P/E ratio of -0.84 and a beta of 0.13. The firm has a ...